BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33619631)

  • 21. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
    J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
    Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
    Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
    Mallick P; Shah P; Gandhi A; Ghose R
    Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
    Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
    Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F
    J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
    van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
    Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
    Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
    Cai X; Tian C; Wang L; Zhuang R; Zhang X; Guo Y; Lu H; Wang H; Li X; Gao J; Li Q; Wang C
    Cancer Biol Ther; 2017 Mar; 18(3):186-193. PubMed ID: 28278081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
    Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
    Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
    Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
    Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
    Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
    Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
    Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
    Fujita K; Ando Y; Nagashima F; Yamamoto W; Eodo H; Araki K; Kodama K; Miya T; Narabayashi M; Sasaki Y
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):515-22. PubMed ID: 17406868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using
    Joshi SS; Catenacci DVT; Karrison TG; Peterson JD; Zalupski MM; Sehdev A; Wade J; Sadiq A; Picozzi VJ; Amico A; Marsh R; Kozloff MF; Polite BN; Kindler HL; Sharma MR
    Clin Cancer Res; 2020 Jan; 26(1):18-24. PubMed ID: 31558477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
    Denlinger CS; Blanchard R; Xu L; Bernaards C; Litwin S; Spittle C; Berg DJ; McLaughlin S; Redlinger M; Dorr A; Hambleton J; Holden S; Kearns A; Kenkare-Mitra S; Lum B; Meropol NJ; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):97-105. PubMed ID: 19415281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.
    Okumura M; Iwakiri T; Takagi A; Hirabara Y; Kawano Y; Arimori K
    Biochem Pharmacol; 2011 Dec; 82(11):1720-30. PubMed ID: 21840303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.